Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,006 DKK | +0.58% | -2.95% | -6.91% |
Apr. 16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
Apr. 16 | Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.91% | 18.64B | |
-3.10% | 102B | |
+2.11% | 96.37B | |
-1.80% | 21.37B | |
-17.75% | 20.92B | |
-42.00% | 16.4B | |
-28.19% | 13.53B | |
+19.90% | 10.85B | |
-23.23% | 8.4B | |
+11.29% | 8.01B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Genmab Says Panel in Daratumumab Arbitration Rules in Favor of Johnson & Johnson Unit